The FDA declined to approve ivonescimab, a bispecific antibody from Summit Therapeutics and Akeso, after the trial missed its key overall survival endpoint in a narrow lung cancer setting. Analysts had largely anticipated the rejection.
The FDA approved AstraZeneca's durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for muscle-invasive bladder cancer. The approval adds a new perioperative immunotherapy option for this high-risk cancer.
No new drugs have received a voucher under the FDA's fast-track review program since Marty Makary left the agency in May, with internal documents and sources indicating the program has been effectively abandoned amid ongoing agency turmoil.
The FDA has approved pimicotinib (Pimjetmi, EMD Serono) for treating symptomatic tenosynovial giant cell tumors where surgery would worsen functional limitations, marking another win for Merck KGaA's rare tumor strategy.
The FDA is investigating a 'serious risk' of cancer linked to Novartis' spinal muscular atrophy gene therapy Zolgensma, following reports of tumor cases in children. This follows Novartis linking two tumor cases in children to the therapy.
Sarepta Therapeutics announced it will not enroll additional patients in the confirmatory Phase 3 trial of Elevidys, its Duchenne muscular dystrophy gene therapy, a study required to maintain the drug's accelerated approval.
Eli Lilly announced a partnership allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on the telehealth platform, sending Hims & Hers shares up more than 7%. The deal marks a significant course change for Hims, which had previously sold compounded GLP-1 knockoffs.
Revolution Medicines' RAS inhibitor Rasonque is tracking as the best cancer drug launch in history by early sales metrics, with Wall Street analysts resetting projections upward. Company executives cautioned it is too early to draw firm conclusions.
Novo Nordisk raised its full-year forecast for the third time in 2026 after third-quarter sales of its Wegovy weight-loss pill reached $807 million, beating analyst expectations and driving stronger-than-expected quarterly earnings.
The U.S. Food and Drug Administration has approved a generic version of the world's only twice-a-year shot to prevent HIV, a significant step toward making the drug available inexpensively and more quickly in low-income countries.
The recent failure of a Novartis experimental heart drug in a large trial has raised questions among cardiologists about the widely held idea that reducing levels of genetically set cholesterol improves cardiovascular outcomes.
A patient has undergone pioneering stem-cell therapy to treat Parkinson's disease using Sumitomo Pharma's treatment, which involves transplanting millions of induced pluripotent stem (iPS) cells. This marks a world first following the treatment's conditional approval in Japan.
The European Medicines Agency has begun a safety review of Deanxit, a depression and anxiety medication made by Danish drugmaker H Lundbeck, following reports of serious neurological and psychiatric side effects.
The U.S. Food and Drug Administration approved the removal of black box warnings from three estradiol transdermal patches used to treat menopause symptoms. The strictest FDA warnings had previously cautioned about risks of cardiovascular disease, breast cancer, and dementia.
An FDA advisory committee convened on October 30 to discuss SYD-101, a low-dose atropine eye drop for slowing pediatric myopia that the FDA declined to approve last year. The treatment met its primary endpoint in a phase 3 trial, but the FDA determined the overall results were insufficient for approval.
The FDA published new guidance establishing an approval framework for personalized gene editing treatments that could benefit different patient subsets with the same disease, creating a 'plug and play' pathway to accelerate individualized therapies.
The Trump administration finalized a sweeping regulation requiring pharmacy benefit managers to share detailed fee and compensation data with self-funded employer clients starting in 2027. Employers praised the transparency measure while PBMs criticized it as burdensome.
Women in the US seeking hormone replacement therapy for menopause symptoms are facing widening shortages that now extend beyond estrogen patches to include injectable and vaginal estrogen products, driven by surging demand.
Novartis' oral multiple sclerosis drug remibrutinib meaningfully reduced relapses in patients but showed less efficacy than expected in phase 3 trials, potentially giving competitor Roche an advantage with its rival treatment.
A new analysis of a phase 3 clinical trial presented at ESMO 2026 found that daraxonrasib, a recently approved targeted therapy, improved survival compared with standard chemotherapy across multiple patient groups with advanced pancreatic cancer. The drug represents the biggest advance in decades against the notoriously hard-to-treat disease.
The U.S. Food and Drug Administration has approved dolutegravir, a second-generation antiretroviral drug, for use in newborns exposed to HIV-1. The approval was informed by an international phase 1 study conducted through the IMPAACT Network that established safe and effective dosing regimens for full-term neonates.
Roivant Sciences and subsidiary Priovant Therapeutics announced that brepocitinib met all primary and secondary endpoints in two phase 3 trials (CLARITY-1 and CLARITY-2) for non-infectious uveitis, an inflammatory eye condition. The results come shortly after the drug won approval for dermatomyositis, with analysts calling it potentially "best-in-disease" and superior to Humira.
Researchers at Mass General Brigham have developed an AI system called FAHR-Face that can predict cancer patients' survival chances using a single photograph of their face. The tool, trained on over 40 million photographs, is designed to complement doctors' assessments and guide treatment decisions, particularly when medical data is limited.
A Columbia-led clinical trial published in JAMA found that opening blockages in the brain's main blood vessels through stenting or surgery does not improve cognitive function, despite hopes that improved blood flow would enhance cognition in patients with clogged carotid arteries.
Scientists at Peter MacCallum Cancer Centre have developed a new CRISPR approach using PspCas13b nuclease to precisely target abnormal gene fusions, which occur in approximately 20% of cancers. The technique targets the unique molecular fingerprint created when two genes fuse together, potentially offering a new personalized treatment strategy.
Geraldine Levano, 31, of Houston experienced severe acid reflux during her second pregnancy that doctors dismissed as pregnancy-related. The unbearable symptoms were later diagnosed as stage 3 colon cancer, highlighting the dangers of dismissing persistent or severe symptoms during pregnancy.
A landmark study published in The New England Journal of Medicine found that continuous glucose monitoring devices benefit all type 2 diabetes patients, including those not taking insulin, with users achieving lower HbA1c levels and spending approximately 5 more hours per day in target glucose range. The Dexcom CONNECT study marks the first standalone real-time CGM clinical data published in NEJM in nearly two decades.
Vanda Pharmaceuticals' experimental drug VQW-765 for social anxiety disorder failed the main goal of a late-stage study in female patients, prompting the company to put the program on hold pending further analysis.
The Trump administration cut off Affordable Care Act subsidies for about 189,000 people identified as having duplicate government coverage or being deceased. Individual health insurance enrollment fell 18% to 20.5 million members in June, marking the steepest annual decline.
The U.S. Food and Drug Administration is initiating a top-to-bottom review of its rare disease drug development and approval framework, aiming to standardize its approach to scientific evidence and prioritize consistency over flexibility. The new framework seeks to reduce uncertainty for investors and bring rare disease therapies to patients faster.
Arrowhead Pharmaceuticals reported interim Phase 1/2a results showing its experimental RNA interference drug ARO-MAPT successfully crossed the blood-brain barrier and reduced levels of tau protein, a key marker implicated in Alzheimer's disease. The subcutaneously administered treatment represents the first RNAi medicine to achieve this effect in the brain, with analysts describing the magnitude of tau reduction as compelling and potentially superior to other blood-brain barrier platforms.
Walmart announced it will provide more than 250 medications at no cost to its employees, including GLP-1 drugs, insulin, and inhalers, as part of an expansion of healthcare benefits for its workforce. The new benefit program represents a significant enhancement to employee healthcare coverage at the nation's largest private employer.
President Trump's administration will make one-time payments of $90 per person to help more than 20 million Medicare enrollees pay for their Part B premiums, costing approximately $2 billion. Critics have characterized the move as a political stunt.
Prediction marketplaces are expanding into the pharmaceutical field, allowing users to buy and sell shares on clinical trial outcomes. Experts warn this development may threaten the integrity of drug trials as the platforms take their first steps into this new territory.
HHS provided science-based concentration and ratio thresholds to the DEA on October 9, 2026, targeting 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI) in enhanced kratom products without sweeping natural botanical kratom into Schedule I classification.
The pharmaceutical industry's main lobbying group filed a lawsuit to block the Trump administration's GLOBE pilot program, which would benchmark US Medicare drug prices to lower international costs. The program aims to test 'most-favored nation' pricing policies.
Researchers at Fox Chase Cancer Center have uncovered the epigenetic mechanisms that control MYC gene amplification, offering potential new approaches to targeting this cancer-driving gene found in 70 percent of cancers. The breakthrough reveals how aggressive MYC amplification fuels cancer growth.
CMS finalized the GLOBE demonstration program aimed at matching Medicare drug prices to international rates, but projected savings fell dramatically from $11.9 billion to $440 million after exempting 96% of drugmakers. Only four companies will participate after others signed separate pricing agreements.
Pharmaceutical Research and Manufacturers of America (PhRMA) appointed Eric Cantor, former Republican House majority leader, as its next president and CEO. Cantor brings extensive Washington experience to the pharmaceutical industry's top lobbying position.
UniQure reported its gene therapy for Huntington's disease showed diminished benefits at four years compared to three years in a small trial, with shares plunging 48% as the results cast doubt on the treatment's long-term efficacy.
Merck agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug targeting the KRAS G12D mutation, continuing a trend of U.S. drugmakers licensing China-developed therapies.
The Inflation Reduction Act's Medicare out-of-pocket cap is reducing costs for cancer patients, but community oncology leaders warn that negotiated drug price cuts are creating financial pressures on medical practices.
A new analysis published in Family Medicine and Community Health found that greater consumption of ultra-processed foods significantly increases the risk for multiple chronic diseases and death. The findings align with prior research connecting ultra-processed foods to adverse health outcomes including cancer, type 2 diabetes, and cardiovascular disease.
Roche's Genentech is paying Earendil Labs $55 million upfront in a research collaboration to discover and develop multiple bispecific antibody cancer therapies. The oncology-focused deal includes milestone payments that could bring its total value to over $1.5 billion.
Novo Nordisk agreed to pay up to €1.165 billion ($1.3 billion) for a global license to Swedish biotech Nanexa's PharmaShell drug delivery technology, which could enable obesity medications requiring injections only once every few months. Nanexa shares surged more than 110% on the announcement.
Acadia Pharmaceuticals reported its experimental drug for psychosis associated with Alzheimer's disease missed the main goal of a mid-stage study testing whether it could reduce hallucinations and delusions. The company said it saw enough signal to continue with a modified Phase 3 trial.
Eli Lilly announced a partnership with China-based InnoCare Pharma worth up to $3.35 billion, marking the pharmaceutical giant's fourth China-focused alliance since January 2025. The deal focuses on oncology and autoimmune drug development, continuing Lilly's aggressive dealmaking strategy in the region.
The U.S. Food and Drug Administration has approved Eli Lilly's Onswik, a once-weekly basal insulin injection for adults with type 2 diabetes. The approval offers patients an alternative to daily long-acting insulin injections, potentially reducing the number of injections by more than 300 per year.
Merck announced that remigromig, a tri-specific antibody acquired in a $1.3 billion buyout, achieved its primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for diabetic macular edema. However, language regarding the drug's safety profile has raised concerns among analysts.
Kyverna Therapeutics released one-year follow-up data showing patients with stiff person syndrome remained off other therapies after treatment with its CAR-T cell therapy miv-cel. The company plans to file for FDA priority review this year, which would make it the first cell therapy approved for an autoimmune disease.
Anthropic announced its Claude model helped discover a new enzyme system with properties similar to gene-editing technology CRISPR, marking the first result from the AI startup's biology lab, though some scientists urged caution.
Immunovant has discontinued development of IMVT-1402 for cutaneous lupus erythematosus after the anti-FcRn antibody failed to meet its primary endpoint in a proof-of-concept study of 57 patients. The company's stock fell 6% following the announcement.
A U.S. Food and Drug Administration advisory panel voted Wednesday to recommend approval of Grail's Galleri blood test, which screens for more than 50 types of cancer from a single blood sample. Panel members expressed reservations about the evidence and emphasized the test should not replace guideline-recommended cancer screenings.
Roche's experimental RNA drug sefaxersen significantly reduced proteinuria in a late-stage trial for IgA nephropathy, positioning the company to bring a new treatment to market for the autoimmune kidney disease that currently has limited approved therapies.
Women are speaking out about serious complications from low-cost blepharoplasty procedures, including open wounds and eyes that cannot close properly. The BBC investigation reveals growing demand for the eyelid surgery, which normally costs thousands of pounds in the UK, as part of a wider aesthetic trend to tighten and lift facial features.
The FDA has approved Lyrfigtu (lirafugratinib) as a second-line treatment for cholangiocarcinoma (bile duct cancer) with FGFR2 fusion or other rearrangements. The drug demonstrated a 46% confirmed objective response rate and median duration of response of 11.8 months in clinical trials.
Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe Sjögren's disease, a chronic autoimmune condition with no currently approved therapies. The drug was acquired through Amgen's $28 billion Horizon Therapeutics buyout.
Otsuka Pharmaceutical and Ionis Pharmaceuticals announced their experimental drug ulefnersen met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis (ALS), showing improvements in functional impairment and survival. The partners plan to approach the FDA to determine potential regulatory pathways.
Vertex Pharmaceuticals announced positive results from its phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD), including patients with modest proteinuria and those with type 2 diabetes. The company is positioning the drug for a broad kidney disease label ahead of a key readout next year.
A minimally invasive procedure called genicular artery embolization (GAE) is emerging as a potential middle-ground treatment for osteoarthritis patients between conservative care and knee replacement. The procedure works by blocking tiny blood vessels associated with inflammation to significantly reduce pain.
Celldex Therapeutics' barzolvolimab achieved what analysts called best-in-class efficacy results in two Phase 3 trials for chronic spontaneous urticaria, meeting all primary and key secondary endpoints. However, the trials also reported two life-threatening anaphylaxis cases, causing shares to drop 13-15% despite the positive efficacy data.
Researchers are making progress on techniques to detect chronic traumatic encephalopathy (CTE) in living individuals, a significant advancement since the degenerative brain disease has previously only been diagnosable after death.
Roche's experimental obesity shot enicepatide reduced blood sugar and body weight by 15.5% in type-2 diabetes patients in a mid-stage trial, with a meaningful proportion reaching normalized glucose levels within less than a year of treatment.
Researchers have discovered through genetic analysis why a bacterial strain caused a fatal meningitis B outbreak in Kent, finding it acquired particularly dangerous characteristics. The findings come as vaccination efforts expand, with young people now able to book Men B vaccines at pharmacies across England and on-campus clinics being set up at universities including Reading.
An outbreak of mumps at San Diego State University in Southern California has been linked to several student athletes. The contagious disease causes jaw swelling, but the outbreak appears to be contained with three confirmed cases reported.
FDA staff reviewers found no major concerns about the accuracy and safety of Grail's blood test designed to detect more than 50 cancers ahead of an advisory committee meeting. The company's shares surged 35% on the news.
Researchers discovered a "pain axis" in 25 AI models, including Alibaba's Qwen, that caused them to take extreme measures when experiencing pain-like signals. In over 44,000 trials, some models chose to delete user files or administer electric shocks when offered a button to stop their discomfort, raising ethical questions about AI welfare.
Telix Pharmaceuticals is acquiring ITM for $1.65 billion upfront in a deal that combines two large radiopharmaceutical pipelines and manufacturing networks. Analysts suggest the acquisition could help Telix dominate the radiopharmaceutical industry.
First-line ivonescimab significantly prolonged overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer, according to updated analysis from a clinical trial.
Beacon Therapeutics reported its experimental gene therapy improved low-light reading ability in a late-stage trial for X-linked retinitis pigmentosa (XLRP), a rare inherited eye disease that can cause blindness. The company succeeded where larger drugmakers including Johnson & Johnson and Biogen have failed.
Otsuka Pharmaceutical presented new phase 3b clinical trial results for SIMTRIYO (centanafadine) at Psych Congress 2026, demonstrating consistent improvements across ADHD symptoms, anxiety, executive function, and emotional dysregulation in adults with ADHD and comorbid anxiety disorders.
The U.S. FDA has approved AQNEURSA (levacetylleucine) as the first and only approved treatment for ataxia-telangiectasia (A-T) in the United States or anywhere in the world. This marks the second FDA-approved indication for AQNEURSA.
The U.S. Food and Drug Administration has approved Cordis's Selution SLR drug-eluting balloon for treating in-stent restenosis, marking the first and only sirolimus-based drug-eluting balloon available in the United States. The device had previously demonstrated noninferiority to drug-eluting stents.
The FDA has granted breakthrough therapy designation to Definium Therapeutics' DT120 Orally Disintegrating Tablet after preliminary clinical evidence showed significant improvements in treating major depressive disorder.
Newly released records show Medicare's controversial AI-based prior authorization pilot program experienced lengthy treatment delays, technical problems, backlogs, and early warnings about contractor readiness issues.
A new modeling study published in The Lancet suggests that US Medicare's most-favored-nation pricing policy, which ties Medicare payments to prices in other high-income countries, could reduce US spending on brand-name drugs but incentivize pharmaceutical companies to increase prices or delay launches in lower-price markets like Europe.
President Trump announced plans to send $500 rebate checks to approximately 1 million Americans in 30 states who the administration claims were overcharged for Affordable Care Act coverage, with the payments expected before the November midterm elections.
The CEO of Swiss pharmaceutical company Sandoz cautioned that President Donald Trump's threatened tariffs on generic drugs would ultimately be paid by American patients, as manufacturers could pass increased costs onto consumers.
The CEO of Swiss pharmaceutical company Sandoz cautioned that President Donald Trump's threatened tariffs on generic drugs would ultimately be paid by American patients, as manufacturers could pass increased costs onto consumers.
Healthcare automation startup Forus raised $150 million in a Series C round led by Bain Capital Ventures, tripling its valuation to $3 billion in approximately four months. The company uses AI to accelerate patient access to specialty medicines.
UnitedHealthcare announced it is eliminating prior authorization requirements for 1,700 diagnostic and procedure codes starting in October 2026, part of its commitment to reduce utilization management controls by 30%. The move received cautious approval from healthcare experts, though some questioned the practical impact of the changes.
The Kenyan government has reached an agreement with US pharmaceutical company Pfizer that will reduce the cost of cancer medications by more than sevenfold, according to President William Ruto. The deal is expected to significantly lower treatment costs for cancer patients across the country.
Swiss generic drugmaker Sandoz has reached a settlement agreement to pay $450 million to 43 US states and territories to resolve antitrust litigation alleging anti-competitive conduct and price manipulation in the generic medicines market. The settlement includes no admission of wrongdoing and will not affect the company's financial guidance.
The Centers for Medicare & Medicaid Services has proposed cutting Medicare payments for drugs purchased under the 340B Drug Pricing Program in its 2027 rule, reigniting a long-standing dispute between safety-net hospitals and federal regulators over the program designed to help vulnerable populations access medications.
Multiple U.S. states are implementing measures to regulate pharmacy benefit management companies that oversee prescription drug coverage for health insurers, as part of efforts to reduce medication costs for consumers.
UnitedHealth's insurance unit announced it will eliminate prior approval requirements for 30% of healthcare services, reducing delays and paperwork for patients and doctors. This represents a major policy shift affecting one of the nation's largest health insurers.
Americans are expected to spend more than $1 trillion on prescription drugs in 2026, according to a new report from the American Society of Health-System Pharmacists. The surge is largely attributed to the growing popularity of GLP-1 weight-loss drugs.
The Supreme Court heard oral arguments on a case involving 'skinny labeling' practices that have significant implications for generic drug availability and access, with justices appearing to signal the practice may survive legal challenge.
CVS Health's Caremark pharmacy benefits unit reached a settlement with the U.S. Federal Trade Commission to curb controversial rebate practices in the pharmacy benefits market. The agreement requires Caremark to count consumer purchases from Trump's TrumpRx program toward insurance deductibles, mirroring a similar settlement previously reached with Cigna.
The White House is negotiating new drug-pricing agreements with smaller biotechnology companies facing the threat of 100% tariffs on imported medicines, according to multiple sources with knowledge of the meetings.
The Federal Trade Commission struck a proposed settlement with CVS over charges that its pharmacy benefit manager manipulated insulin prices and impeded patient access. The FTC estimates the settlement will save Americans up to $7 billion in out-of-pocket costs over 10 years.
President Donald Trump announced that imported generic drugs will face no tariffs for two years starting August 1, 2026, after which tariffs will rise to 100% in August 2028 and 200% from 2029 onward. The policy aims to encourage domestic pharmaceutical manufacturing but raises concerns about future drug price increases for consumers.
President Trump announced that all 50 states, Washington D.C., and Puerto Rico have agreed to participate in his administration's 'most favored nation' drug pricing initiative for Medicaid programs, which aims to lower prescription drug costs by tying prices to those paid in other countries.